TOI logo

ONCOLOGY INSTITUTE INC/THE

TOINASDAQ
πŸ† #2345 by market capEarnings Nov 11US Equity
$5.12β–² $0.26 (+5.13%)
Market closed Β· at close
1hβ€”
24hβ–² 5.1%
7dβ–² 0.0%
14dβ–² 7.7%
30dβ–Ό 18.1%
1yβ–² 24.6%
🏦Market Cap
$512M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+35.4%
High Growth
πŸ“ŠGross Margin
15.1%
Thin
πŸ’΅FCF Margin
0.4%
Thin
βš–οΈP/S Ratio
0.9x
Cheap
Otter Score
44
Weak

Trading Snapshot

Day Range
$5.09 – $5.22
52-Week Range
$2.32 – $7.05
Volume
$3.59B
Avg Volume
$4.76B
Shares Outstanding
100.0M
Next Earnings
Sep 2, 2026

Fundamentals Snapshot

Annual Revenue
$503M
Last Q Revenue
$161M
P/E Ratio
β€”
P/S Ratio
0.9x
EPS (TTM)
$-0.45
Dividend Yield
β€”

Why Investors Own TOI

  • βœ“High-growth profile β€” revenue up +25.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 34% gross margin and 4% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$503Mβ–² +23.9% YoY
Gross Margin (TTM)
33.9%β–² +3.6% YoY
Operating Income (TTM)
$49Mβ–² +23.9% YoY
Free Cash Flow (TTM)
$22Mβ–² +23.9% YoY

About ONCOLOGY INSTITUTE INC/THE

The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
44/100

Analyst Price Target

β“˜
Average Target
$5.22
β–² +1.9% Upside
High Target$6.55
Low Target$4.34
Based on 16 analysts

Latest News & Updates